A study of the psychological, cognitive and physiological effects of Psychedelic Medicines (ASSESS)
This non-randomized trial (n=100) investigates the psychological, cognitive, and physiological effects of a single session of psychedelic drug exposure with either psilocybin or MDMA in a group setting.
Details
Open, non-randomised interventional study of single-dose psilocybin or MDMA in healthy, trained participants; allocation by participant preference with sessions delivered individually or in small groups (2–6).
Dosing sessions last ~8 hours with two therapists present; a preparatory session (45–90 minutes) is provided. Primary assessments include psychological, cognitive and physiological measures (e.g., DASS), with secondary electrophysiological outcomes such as EEG N100.
A subset of participants may optionally cross over to receive the alternate substance at least three months later; outcomes are repeated pre- and post-exposure.